Blog

OTTAWA, ON / ACCESS Newswire / May 22, 2025 / OakWood Designers & Builders, one of Ottawa’s most respected and enduring home construction firms, has been recognized with the 2025 Consumer Choice Award in the Home Builder category. This milestone achievement honours OakWood’s unparalleled legacy of craftsmanship, client-first design, and visionary use of technology that continues to set new benchmarks for the residential building industry in Canada’s capital.

Founded in 1956 by German master carpenter John Liptak Sr., OakWood started as a modest carpentry business and has since grown into a fourth-generation, family-run powerhouse. Today, under the leadership of Patricia Liptak-Satov and Angela Mallon, the company is celebrated for its award-winning Design + Build services, cutting-edge technology integration, and exceptional commitment to client satisfaction. From custom homes to large-scale renovations and multi-unit developments, OakWood continues to lead by example.

“It’s a tremendous honour to receive the Consumer Choice Award,” said Patricia Liptak-Satov, COO of OakWood. “This recognition reaffirms our team’s commitment to excellence at every stage of a project-from design and material selection to construction and post-completion care. We’re proud to have earned the trust of our clients, and we’re excited to keep raising the bar for what’s possible in home building.”

A Full-Service Design + Build Leader

OakWood offers a complete, vertically integrated approach to residential construction. Clients benefit from in-house architectural and interior designers, professional project managers, skilled trades, and Ottawa’s most advanced construction showroom experience. Its award-winning Design Centres-located in Ottawa South and Downtown-showcase thousands of premium materials, finishes, fixtures, and smart home technologies to help clients bring their visions to life.

Core offerings include:

• Custom homes with net-zero and energy-efficient options

• Full-home renovations and additions

• High-end kitchens and bathrooms

• Multi-unit developments

• Architectural design, permitting, and project management

Every project is supported by OakWood’s industry-leading client portal, which offers real-time updates, financial transparency, and milestone tracking-ensuring a stress-free experience from concept to completion.

A Technology-Driven Approach to Modern Building

What sets OakWood apart is not only its decades-long legacy, but also its commitment to innovation. The company is a national leader in smart home integration, sustainable building practices, and prefabrication solutions. OakWood was one of the first builders in Canada to offer Net-Zero Ready Homes, and it continues to lead the charge in green construction with eco-conscious designs that minimize environmental impact without compromising on luxury.

The firm’s use of virtual reality, 3D modeling, and AI-enhanced design tools further streamlines the process and allows homeowners to engage with their spaces before construction begins-enhancing confidence and satisfaction.

Award-Winning Excellence Recognized

The Consumer Choice Award is based on independent market research and community feedback. Winners are selected based on brand reputation, customer satisfaction, and industry performance. OakWood’s recognition as the top Home Builder in Ottawa highlights not only its exceptional output, but also its consistent ability to evolve and lead in a highly competitive market.

In addition to this latest honour, OakWood has received over 180 local, national, and international awards for design, innovation, and business excellence. The company has been recognized by the Greater Ottawa Home Builders’ Association (GOHBA), Ontario Home Builders’ Association (OHBA), and has achieved distinctions from the Better Business Bureau and Canadian Home Builders’ Association.

Looking Ahead: Building the Future of Home Living

As the residential landscape continues to shift, OakWood remains firmly focused on anticipating client needs and shaping the future of the industry. From expanding its sustainable building offerings to launching design initiatives that reflect Canada’s evolving lifestyles, the company is always several steps ahead.

“Our clients aren’t just building homes-they’re investing in better ways to live,” added Patricia. “That’s why we continue to innovate, hire the best people, and deliver work that exceeds expectations. This award is for them as much as it is for us.”

To learn more about OakWood Designers & Builders or to schedule a consultation, CLICK HERE or visit www.oakwood.ca.

About Consumer Choice Award:
Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.

Contact Information:
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

ADELAIDE, AUSTRALIA / ACCESS Newswire / May 21, 2025 / Barton Gold Holdings Limited (ASX:BGD) (Barton or the Company) advises that the attached announcement has been released to the market.

A copy of this announcement can be accessed on the ASX website, the investor section of Barton’s website, or directly by clicking here.

Authorised by the Managing Director of Barton Gold Holdings Limited.

For further information, please contact:

Alexander Scanlon Managing Director a.scanlon@bartongold.com.au +61 425 226 649

Jade Cook Company Secretary cosec@bartongold.com.au +61 8 9322 1587

About Barton Gold
Barton Gold is an ASX, OTCQB and Frankfurt Stock Exchange listed Australian gold developer targeting future gold production of 150,000ozpa with 1.7Moz Au & 3.1Moz Ag JORC Mineral Resources (64.0Mt @ 0.83 g/t Au), brownfield mines, and 100% ownership of the region’s only gold mill in the renowned Gawler Craton of South Australia.*

Competent Persons Statement & Previously Reported Information
The information in this announcement that relates to the historic Exploration Results and Mineral Resources as listed in the table below is based on, and fairly represents, information and supporting documentation prepared by the Competent Person whose name appears in the same row, who is an employee of or independent consultant to the Company and is a Member or Fellow of the Australasian Institute of Mining and Metallurgy ( AusIMM ), Australian Institute of Geoscientists ( AIG ) or a Recognised Professional Organisation (RPO). Each person named in the table below has sufficient experience which is relevant to the style of mineralisation and types of deposits under consideration and to the activity which he has undertaken to quality as a Competent Person as defined in the JORC Code 2012 (JORC).

Activity	Competent Person	Membership	Status
Tarcoola Mineral Resource (Stockpiles)	Dr Andrew Fowler (Consultant)	AusIMM	Member
Tarcoola Mineral Resource (Perseverance Mine)	Mr Ian Taylor (Consultant)	AusIMM	Fellow
Tarcoola Exploration Results (until 15 Nov 2021)	Mr Colin Skidmore (Consultant)	AIG	Member
Tarcoola Exploration Results (after 15 Nov 2021)	Mr Marc Twining (Employee)	AusIMM	Member
Tunkillia Exploration Results (until 15 Nov 2021)	Mr Colin Skidmore (Consultant)	AIG	Member
Tunkillia Exploration Results (after 15 Nov 2021)	Mr Marc Twining (Employee)	AusIMM	Member
Tunkillia Mineral Resource	Mr Ian Taylor (Consultant)	AusIMM	Fellow
Challenger Mineral Resource	Mr Dale Sims (Consultant)	AusIMM / AIG	Fellow / Member

The information relating to historic Exploration Results and Mineral Resources in this announcement is extracted from the Company’s Prospectus dated 14 May 2021 or as otherwise noted in this announcement, available from the Company’s website at www.bartongold.com.au or on the ASX website www.asx.com.au. The Company confirms that it is not aware of any new information or data that materially affects the Exploration Results and Mineral Resource information included in previous announcements and, in the case of estimates of Mineral Resources, that all material assumptions and technical parameters underpinning the estimates, and any production targets and forecast financial information derived from the production targets, continue to apply and have not materially changed. The Company confirms that the form and context in which the applicable Competent Persons’ findings are presented have not been materially modified from the previous announcements.

Cautionary Statement Regarding Forward-Looking Information
This document may contain forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “expect”, “target” and “intend” and statements than an event or result “may”, “will”, “should”, “would”, “could”, or “might” occur or be achieved and other similar expressions. Forward-looking information is subject to business, legal and economic risks and uncertainties and other factors that could cause actual results to differ materially from those contained in forward-looking statements. Such factors include, among other things, risks relating to property interests, the global economic climate, commodity prices, sovereign and legal risks, and environmental risks. Forward-looking statements are based upon estimates and opinions at the date the statements are made. Barton undertakes no obligation to update these forward-looking statements for events or circumstances that occur subsequent to such dates or to update or keep current any of the information contained herein. Any estimates or projections as to events that may occur in the future (including projections of revenue, expense, net income and performance) are based upon the best judgment of Barton from information available as of the date of this document. There is no guarantee that any of these estimates or projections will be achieved. Actual results will vary from the projections and such variations may be material. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. Any reliance placed by the reader on this document, or on any forward-looking statement contained in or referred to in this document will be solely at the readers own risk, and readers are cautioned not to place undue reliance on forward-looking statements due to the inherent uncertainty thereof.

* Refer to Barton Prospectus dated 14 May 2021 and ASX announcement dated 4 March 2025. Total Barton JORC (2012) Mineral Resources include 909koz Au (30.8Mt @ 0.92 g/t Au) in Indicated category and 799koz Au (33.2Mt @ 0.75 g/t Au) in Inferred category, and 3,070koz Ag (34.5Mt @ 2.80 g/t Ag) in Inferred category as a subset of Tunkillia gold JORC (2012) Mineral Resources.

SOURCE: Barton Gold Holdings Limited

View the original press release on ACCESS Newswire

LAS VEGAS, NEVADA / ACCESS Newswire / May 21, 2025 / ALT5 Sigma Corporation (the “Company” or “ALT5”) (NASDAQ:ALTS)(FRA:5AR1), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, today announces June 2, 2025 as the record date for the previously announced transaction involving further steps in the Company’s formal separation of its healthcare assets, known as Alyea Therapeutics Corporation (“Alyea”). As previously announced, the Company has decided to separate its healthcare and fintech segments to allow each entity to concentrate on its unique business needs.

The Company expects that it will announce the scope and method of a partial or full disposition of its interests in Alyea, whether as a split-off or a spin-off or another related transaction, later this year, but wanted to provide its stakeholders and the market with a specific record date for such transaction. All record and beneficial holders of equity in the Company and all holders of equity underlying various securities of the Company on the record date, where applicable, will be able to participate in the distribution of Alyea in a transaction, the details of which are yet to be announced. No vote of the equity holders of the Company is required as of the date of this press release or as of the record date. The Company will advise its stakeholders and the market if a vote of the “record date security holders” of the Company will be required in connection with an Alyea distribution.

About ALT5 Sigma Corporation
ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1) is a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing settlement, payment and safe keeping of digital assets. The Company is one of the constituents of the Russell Microcap Index, as of June 28, 2024.

Founded in 2018, ALT5 Sigma, Inc. (a wholly owned subsidiary of ALT5 Sigma Corporation), provides next-generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Sigma, Inc., through its subsidiaries, offers two main platforms to its customers: “ALT5 Pay” and “ALT5 Prime.” ALT5 Sigma has processed over $5 billion USD in cryptocurrency transactions since inception.

ALT5 Pay is an award-winning cryptocurrency payment gateway that enables registered and approved global merchants to accept and make cryptocurrency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay’s checkout widgets and APIs. Merchants have the option to convert to fiat currency(s) automatically or to receive their payment in digital assets.

ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named “ALT5 Pro” that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime’s FIX API, as well as through Broadridge Financial Solutions’ NYFIX gateway for approved customers.

The Company is working on the separation of our biotech business that will move forward under “Alyea Therapeutics Corporation.” Through its biotech activities, the Company is focused on bringing to market drugs with non-addictive pain-relieving properties to treat conditions that cause chronic or severe pain. Our patented product, a novel formulation of low-dose naltrexone (JAN123), is being initially developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. The FDA has granted Jan123 Orphan Drug Designation for treatment of CRPS.

About Alyea Therapeutics Corporation
Alyea, an ALT5 company, is developing innovative, actionable solutions intended to help end the opioid crisis. Alyea is dedicated to funding resources toward innovation, technology, and education to find a key resolution to the national opioid epidemic, which is one of the deadliest and most widespread in the nation’s history. Its drugs in the clinical trial pipeline have shown promise for their innovative targeting of the causes of pain as a strategic option for physicians averse to exposing patients to addictive opioids.

Forward-Looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the profitability and prospective growth of ALT5’s platforms and business, that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5’s services, and technology challenges for future growth or expansion. This press release also contains general statements relating to risks that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as “continue”, “expect”, “intend”, “will”, “hope”, “should”, “would”, “may”, “potential”, and other similar expressions. Such statements reflect the Company’s current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies. This press release also contains statements that are forward-looking in respect of the expected future partial or full disposition of the Company’s interests in Alyea without specific=ty of the scope or methods thereof.

Many factors could cause the Company’s actual results, performance, or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in the Company’s filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Media Contact Investor Relations
IR@alt5sigma.com
1-800-400-2247

SOURCE: ALT5 Sigma Corp

View the original press release on ACCESS Newswire

Strategic media partnership will amplify AINOS’s brand and innovation story across major financial networks and digital platforms

NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / AINOS, Inc. (NASDAQ:AIMD), a diversified biotech and AI-driven diagnostics company, has signed a long-form broadcast and commercial media agreement with New to The Street, a leading provider of televised investor communications. As part of the agreement, AINOS will be featured in monthly long-form interview segments and nationally broadcast commercials across:

• CNBC

• FOX Business

• Bloomberg Television

• New to The Street’s YouTube channel, with 2.51 million subscribers and growing

The content will spotlight AINOS’s leadership, product pipeline, and forward-looking strategy to a broad base of retail and institutional investors.

“We’re excited to partner with New to The Street to elevate our story at a time of rapid growth,” said [AINOS Executive Name/Title]. “With national TV exposure and recurring digital placement, this agreement provides a powerful platform to reach investors globally.”

New to The Street, known for its televised presence at the NYSE and Nasdaq MarketSite, has helped hundreds of emerging growth companies expand visibility through a combination of earned, sponsored, and digital media.

The AINOS campaign will also include a custom segment intro, with recurring broadcast features and cross-platform exposure across NTTS’s investor-focused ecosystem.

“We’re proud to welcome AINOS to our expanding lineup of innovators,” said Vince Caruso, CEO of New to The Street. “Their science-first approach and strategic outlook make them a natural fit for our audience and broadcast platforms.”

The first segment is scheduled to air in June 2025, with subsequent features rolling out monthly.

For media inquiries, contact:

Monica Brennan
Media Relations – New to The Street
monica@newtothestreet.com

SOURCE: New To The Street

View the original press release on ACCESS Newswire

LONDON, UNITED KINGDOM / ACCESS Newswire / May 21, 2025 / Feeding your dog or cat might be doing more damage to the planet than you think.

A new study has revealed that conventional meat-based pet food carries a largely unrecognized environmental cost – contributing significantly to land use, greenhouse gas (GHG) emissions, and climate breakdown. The review, just published, found that pet food production is closely tied to the livestock industry, which is responsible for at least one-fifth of annual global GHG emissions.

With the world’s pet population now approaching one billion animals, the impacts are no longer minor. In the United States alone, dog and cat diets account for 25-30% of the environmental toll of livestock farming. One analysis even found that a single medium-sized dog’s diet in Japan had a greater environmental footprint than the average Japanese person’s diet.

But experts say there’s a powerful – and practical – solution. Stated Billy Nicholles, the lead author, “Switching pets to nutritionally sound vegan diets significantly mitigates our dogs and cats’ environmental ‘paw prints.’ It’s a huge opportunity to reduce the environmental burden of our food system.”

The study examined 21 existing analyses of pet food sustainability and concluded that diet was the single largest factor driving environmental impacts. Protein choice was key: pet foods rich in animal ingredients were consistently linked to much larger environmental impacts.

By contrast, vegan pet diets – where formulated to be nutritionally sound – offered major reductions across all impact categories. If all pet dogs worldwide were fed a vegan diet, the resulting food energy savings could feed 450 million people, according to the study. Greenhouse gas savings would exceed the UK’s annual emissions.

“This offers huge potential,” said Professor Andrew Knight, co-author and veterinary expert. “Modern vegan pet foods are not only safe, but often healthier. And they’re vastly more sustainable.”

The report also pointed to emerging innovations like cultivated meat and precision-fermented proteins, which are beginning to enter the pet food market. These alternatives promise the taste and nutrition of meat without the massive environmental burden.

With consumer demand growing, the authors urge governments, brands, and the public to rethink what goes into pet food bowls. “Sustainable pet food isn’t just a niche trend,” said Nicholles. “It’s a climate solution hiding in plain sight.”

Contact Information

Billy Nicholles
Pet food researcher
billy@bryantresearch.co.uk
+44 7921461778

Andrew Knight
Veterinary Professor of Animal Welfare
andrew.knight@murdoch.edu.au

SOURCE: Sustainable Pet Food Foundation

View the original press release on ACCESS Newswire

Investment from largest shareholder strengthens balance sheet, signals insider conviction, and funds Telomir-1’s upcoming IND submission for a rare disease indication

MIAMI, FLORIDA / ACCESS Newswire / May 21, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir” or the “Company”), an emerging leader in age-reversal science, today announced it has secured $3 million in equity financing, through a direct investment by The Bayshore Trust, the Company’s largest shareholder.

The transaction involved the purchase of 1 million restricted shares of the Company’s common stock at $3.00 per share, representing an 18% premium to Telomir’s closing share price of $2.54 on the date of execution. The transaction was structured as a straight restricted common stock transaction with no warrants, no discounts, and no convertible features.

This transaction follows a prior $1 million equity investment at $7.00 per share made on December 9, 2024, through The Starwood Trust-an entity affiliated with the Company’s largest shareholder – and complements an existing $5 million non-dilutive line of credit from the same affiliated group, which remains undrawn.

“We’ve now raised $4 million in equity and secured a $5 million credit line – all through affiliated entities on shareholder-friendly terms,” said Erez Aminov, Chairman and CEO of Telomir. “These investments included no warrants, no discounts, and no toxic structures. Every financing decision we make is grounded in a long-term view of shareholder value, and this raise reflects that discipline.”

From an operational standpoint, our first goal is to submit our IND by year-end and generate early human efficacy data in the most efficient and capital-responsible way. We believe pursuing a rare disease indication gives us a strategic entry point to demonstrate clinical impact and build broader value.

Advancing a Growing Pipeline with Breakthrough Potential

Telomir is advancing two highly innovative drug candidates: Telomir-1, a first-in-class age-reversal molecule targeting the root causes of cellular decline, and Telomir-Ag2, a stabilized Silver(II) compound designed to address the growing threat of drug-resistant infections.

Telomir-1: Reversing Aging, Treating Disease, and Extending Longevity

Telomir-1 is an oral small molecule that addresses five fundamental biological drivers of aging and chronic disease: mitochondrial dysfunction, oxidative stress, calcium imbalance, toxic metal accumulation (iron and copper), and telomere shortening.

In preclinical models, Telomir-1 has demonstrated:

• Reversal of the biological clock, improving both lifespan and health span

• Improvement of mitochondrial energy production in metabolically stressed cells

• Reduction of oxidative stress (ROS), a key contributor to age-related damage

• Correction of calcium signaling pathways associated with neurodegeneration and cell death

• Protection against metal-induced toxicity from iron and copper

• Telomere lengthening and stabilization to support cellular regeneration

Therapeutic potential has been demonstrated across several critical indications:

• Progeria: Telomir confirms lifespan restoration and normalization of accelerated aging in a preclinical model of Progeria, a rare genetic disorder causing rapid aging

• Type 2 diabetes: Telomir-1 reversed insulin resistance, lowered fasting glucose, and improved glucose homeostasis in zebrafish models

• Wilson’s disease: Telomir-1 protected cells from copper-induced toxicity, restoring mitochondrial function and reducing oxidative stress

• Oncology: In a prostate cancer mice model, Telomir-1 reduced tumor volume by approximately 50%

• Chemotherapy support: Co-administration with Paclitaxel prevented mortality in animals otherwise experiencing toxicity

• Retinal and neural protection: In vitro studies showed strong protection of human retinal cells from oxidative and metal stress conditions

These results support the advancement of Telomir-1 in multiple rare and high-value indications, including:

• Progeria and Werner Syndrome

• Wilson’s Disease

• Type 2 Diabetes

• Autism Spectrum Disorder (ASD)

• Spasmodic Dysphonia (SD)

• Age-related Macular Degeneration (AMD)

Telomir plans to engage with the FDA through the Rare Disease Endpoint Advancement (RDEA) Pilot Program, which supports the development of novel clinical endpoints for underserved conditions. In parallel, the Company is advancing a rare disease indication aligned with Telomir-1’s mechanism of action to efficiently generate early human efficacy data and support broader clinical development.

Telomir-Ag2: Stabilized Silver(II) for Drug-Resistant Infections

Telomir-Ag2 is a novel Silver(II) complex stabilized using Telomir’s proprietary chelation platform. Silver(II) has historically shown strong antimicrobial potential but has remained clinically impractical due to its instability-until now.

Preclinical studies demonstrate that Telomir-Ag2 is active against:

• Escherichia coli

• Pseudomonas aeruginosa

• Enterococcus faecalis

• Staphylococcus aureus

• Methicillin- and aminoglycoside-resistant Staphylococcus aureus (MARSA)

Key features include:

• Superior antimicrobial performance over Silver(I) in minimum inhibitory concentration (MIC) assays

• No sulfa-based compounds, minimizing allergic and cytotoxic risks

• Broad potential as a topical product across burn treatment, wound care, and surgical infection prevention

Telomir-Ag2 addresses a growing global market projected to exceed $30 billion across antimicrobial dressings, hospital-acquired infection prevention, and wound care.

“Telomir-Ag2 may be the first stabilized Silver(II) compound viable for medical use,” said Dr. Itzchak Angel, Chief Scientific Advisor of the Company. “It’s broad-spectrum activity, especially against resistant strains, represents a major advancement in antimicrobial science.”

Cautionary Note Regarding Forward-Looking Statements

This press release, statements of Telomir’s management or advisors related thereto, and the statements contained in the news story linked in this release contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.

Any forward-looking statements in this press release are based on Telomir’s current expectations, estimates and projections only as of the date of this release. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir’s programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Helga Moya
info@telomirpharma.com
(786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc

View the original press release on ACCESS Newswire

Acquisition strengthens nationwide telehealth coverage, advancing access to critical and specialized care for hospitals nationwide

NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Equum Medical, one of the nation’s leading providers of acute telehealth-enabled clinical workforce solutions, today announced it has acquired the clinical health services of VeeOne Health, including its Tele-Psychiatry, Tele-Neurology, Tele-Infectious Disease (Tele-ID), Tele-Pulmonary and Tele-ICU service lines. This strategic acquisition expands Equum’s comprehensive telehealth offerings across the care continuum and reinforces its recognized market leadership in acute care telehealth. The combined entity now will support physician service coverage in over 200 hospitals and post-acute facilities nationwide.

With the addition of VeeOne’s capabilities, Equum accelerates its mission to improve healthcare access and outcomes for hospitals and health systems. Tele-Psychiatry services will enable partner hospitals to provide 24/7 emergency and acute psychiatric care virtually, addressing the nationwide shortage of mental health specialists. Likewise, Tele-Neurology services (including on-demand stroke neurologists and other neuro-specialists) will allow rapid neurological consultations in emergency and acute settings, ensuring patients receive timely expert care regardless of location.

Dr. Corey Scurlock, CEO and Founder of Equum Medical, stated, “The acquisition of VeeOne Health’s services represents an exciting opportunity to continue expanding the reach and depth of Equum’s acute care telehealth offerings. By adding these critical service lines, Equum further solidifies its position as a comprehensive partner to hospitals nationwide. We are committed to ensuring that our expanded services bring even greater value to our customers and improved outcomes for patients.”

Ijaz Arif, CEO of VeeOne Health, added, “Equum Medical is an ideal home for VeeOne’s clinical services portfolio. Over the years, we have built robust telehealth programs that have made a real impact for our clients. Joining forces with Equum – a market leader in acute telehealth – means our customers will now benefit from a full spectrum of high-acuity telehealth solutions under one roof. Equum’s commitment to clinical quality and innovation mirrors our own, and we are confident that together, we will continue to provide exceptional virtual care services to healthcare organizations nationwide. This is a win for our clients and for the future of telehealth.” Following this transaction, VeeOne Health Inc. will continue to devote its focus on leading innovation in the virtual healthcare market, supporting healthcare organizations worldwide through its AI-based products to enhance patient care in areas such as remote patient monitoring (RPM), hospital at home, acute inpatient care, ambulatory services, care coordination, and virtual nursing.

Strategic Rationale and Impact:

The acquisition comes at a pivotal time in healthcare, as hospitals face persistent workforce shortages and a rising demand for specialized care. By integrating VeeOne’s tele-specialty services, Equum Medical strengthens its position as a one-stop solution for hospitals seeking to augment staff and expand specialist coverage through virtual care. Equum’s expanded service portfolio is designed to address hospital needs addressing patient flow and through this announcement now spans serviceability pillars of both Access and Capacity. The Access Suite including multi-specialty services of Tele-Stroke, Tele-Neurology, Tele-Psychiatry, Tele-Pulmonology, Tele-Infectious Disease, Tele-Cardiology, Tele-Nephrology, and high acuity physician services of Tele-Critical Care, and Tele-Hospitalist and a Capacity Suite including virtual nursing, virtual safety sitter and observation programs, and telemetry monitoring with extensions into post-acute with Remote Patient Monitoring.

Market Leadership:

This acquisition also highlights the strength of Equum Medical’s leadership team and market strategic position. Equum is included in Becker’s Hospital Review Top Telehealth Companies to Know and prior to the global HIMSS event in Las Vegas in March 2025, Equum Medical was recognized as the #1 Vendor by market research firm Black Book Market Research in Tele-Critical Care and Virtual Nursing Solutions as well as overall Outsourced Virtual Clinician Services. For the executive team, Dr. Scurlock is a national speaker at such events as American Telemedicine Association Annual Conference (NEXUS) and National Rural Health Association (NRHA) and was recognized as one of the Top Digital Health Leaders by Slice of Healthcare for his impactful work in virtual care while Kristen Lawton, MSN, RN Equum’s Chief Nursing Officer, was honored among Becker’s “Women in Health IT to Know” (2024). Under their leadership, Equum has cultivated a culture of clinical excellence and innovation – a culture that will extend to the integration of VeeOne’s services.

Media Contact:

Karsten Russell-Wood
Chief Marketing & Experience Officer
karsten.russell-wood@equummedical.com
(T) 410-409-7376

Press Kit & Further Information: Please visit the Equum Medical website at www.equummedical.com or contact our media relations team (marketing@equummedical.com) for more details.

About Equum Medical: Equum Medical is a technology-enabled inpatient clinical services company recognized for its comprehensive acute care portfolio, now with expanded coverage in Tele-Neurology, Stroke and Psychiatry. Equum leverages advanced telehealth technologies to enhance clinical access and optimize healthcare delivery across hospitals in the United States. By addressing workforce challenges and improving operational efficiency, Equum Medical empowers healthcare systems to elevate patient care, optimize leadership, and achieve positive clinical, operational, and financial outcomes. For more information, visit www.equummedical.com.

About VeeOne Health: Based in Roseville, CA, VeeOne Health is a global leader in the Virtual Care technology, and operations. Founded in 2016, VeeOne Health has the most advanced telemedicine solutions for the entire continuum of care – from acute care settings to outpatient and remote patient monitoring. For more information about VeeOne Health’s vision for the future of telemedicine see https://veeonehealth.com/

SOURCE: Equum Medical

View the original press release on ACCESS Newswire

CEPM offers enterprises a proactive approach to cloud optimization integrated into engineering workflows, and drives immediate savings and long-term efficiency.

NEW YORK, NY / ACCESS Newswire / May 21, 2025 / PointFive, a leading provider of innovative cloud efficiency solutions, announced the launch of Cloud Efficiency Posture Management (CEPM), a new category of cloud optimization technology designed for enterprise engineering and FinOps teams. Inspired by the Cloud Security Posture Management (CSPM), CEPM represents a shift from periodic cost reviews to an always-on, strategic discipline for managing cloud efficiency across an organization.

Traditional cloud cost management tools typically emphasize financial reporting and surface-level optimizations. They neglect deeper technical inefficiencies, resulting in missed opportunities and limited accountability from engineering teams. CEPM addresses this critical gap by proactively detecting hidden cloud waste, providing context, and actionable recommendations.

“We started PointFive to solve cloud inefficiency at its root – the technical, operational reasons – not just surface-level cost management,” said Alon Arvatz, CEO and Founder of PointFive. “Our new CEPM approach makes cloud efficiency as routine and automatic as cloud security, embedding ongoing optimization deeply into daily engineering processes. This shift is essential for enterprises to realize sustainable efficiency at scale.”

“When we started exploring CEPM across different cloud providers, we were struck by how profoundly each platform’s unique metrics influence efficiency,” said Dor Azouri, VP of Research at PointFive. “Traditional tools overlook this because their focus is surface-level visibility. With DeepWaste™, context is everything. The significant savings we uncovered were eye-opening.”

Key features of CEPM include:

• Deep Optimization Insights: Identifies subtle inefficiencies missed by traditional tools, providing actionable, engineer-friendly recommendations.

• Seamless Workflow Integration: Directly integrates widely-used engineering platforms like Jira and ServiceNow and communication platforms like Slack and Teams, embedding efficiency management into everyday tasks without disruption.

• Rapid ROI and Immediate Impact: Enterprises such as Blackhawk Network (BHN), E.ON, Elastic, and Fanatics have already seen increased efficiency and significant cost savings within weeks of deployment.

• Frictionless, Rapid Deployment: CEPM’s agentless architecture enables deployment in a single integration, providing immediate visibility into inefficiencies and opportunities.

• Unique Azure Insights and Expanded Multi-Cloud Optimization: PointFive fully supports Microsoft Azure, AWS, and GCP. The importance of CEPM becomes even more evident in multi-cloud environments, where each provider surfaces different metrics, cost structures, and usage patterns. Azure, for example, reveals inefficiencies that may never appear in AWS, making cross-cloud efficiency difficult to standardize manually. CEPM bridges these gaps. It automates the discovery of cloud-specific opportunities while providing a unified, organization-wide view of efficiency posture. Early Azure adopters have uncovered millions in savings from inefficiencies unique to Azure’s environment.

Customers like BHN have successfully streamlined cloud optimization practices through CEPM, fostering deeper engineering engagement and sustained cost efficiencies.

“Cloud optimization should not be a periodic task or reactive exercise,” Arvatz emphasized. “CEPM empowers engineering teams to continuously embed efficiency into daily operations. The result is sustainable cloud savings, improved reliability, and increased agility – delivering strategic value far beyond simple cost-cutting.”

To learn more about CEPM and how PointFive is redefining cloud optimization, visit www.pointfive.co.

About PointFive
PointFive delivers innovative cloud efficiency solutions for enterprise engineering and FinOps teams. Its Cloud Efficiency Posture Management (CEPM) platform offers deep, actionable insights, continuous optimization, and measurable outcomes, enabling enterprises to proactively manage cloud resources and achieve sustainable efficiency.

Media Contact:

Omri Hurwitz
omri@omrihurwitz.com

SOURCE: Pointfive

View the original press release on ACCESS Newswire

HOUSTON, TEXAS / ACCESS Newswire / May 21, 2025 / EON Resources Inc. (NYSE American:EONR) (“EON” or the “Company”) is an independent upstream energy company with oil and gas properties in the Permian Basin. Today, the Company posted an updated investor deck and the first quarter of 2025 earnings call deck to the Company’s website: https://www.eon-r.com/presentations.

About the Oil Field Property

In November 2023, the Company acquired LH Operating, LLC (“LHO”) including its holdings in New Mexico of oil and gas waterflood production comprising 13,700 contiguous leasehold acres, 342 producing wells and 207 injection wells situated on 20 federal and 3 state leases in the Grayburg-Jackson Oil Field. The Grayburg-Jackson Oil Field is located on the Northwest Shelf of the prolific Permian Basin in Eddy County, New Mexico.

Leasehold rights of LHO, now a wholly owned subsidiary of the Company, include the Seven Rivers, Queen, Grayburg and San Andres intervals that range from as shallow as 1,500 feet to 4,000 feet in depth. The December 2023 reserve report from our third-party engineer, William H. Cobb and Associates, Inc. (“Cobb”), reflects LHO to have proven reserves of approximately 15.4 million barrels of oil and 3.5 billion cubic feet of natural gas. The mapped original-oil-in-place (“OOIP”) in the LHO leasehold is approximately 876 million barrels of oil in the Grayburg and San Andres intervals and 80 million barrels in the Seven Rivers interval for a total OOIP of approximately 956,000,000 barrels of oil.

Our primary production is currently from the Seven Rivers zone. In addition to proven reserves, the Company believes it may access an additional 34 million barrels of oil by adding perforations in the Grayburg and San Andres formations. With proven oil reserves of over 15 million barrels, combined with the potential 34 million additional barrels from the Grayburg and San Andres zones, LHO should produce oil and a revenue stream for more than two decades with a low decline rate.

About EON Resources Inc.

EON is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in the United States. EON’s long-term goal is to maximize total shareholder value from a diversified portfolio of long-life oil and natural gas properties built through acquisition and through selective development, production enhancement, and other exploitation efforts on its oil and natural gas properties.

EON’s Class A Common Stock trades on the NYSE American Stock Exchange (NYSE American: EONR) and the Company’s public warrants trade on the NYSE American Stock Exchange (NYSE American: EONR WS). For more information on EON, please visit the Company’s website: https://eon-r.com/.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to differ materially from what is expected. Words such as “expects,” “believes,” “anticipates,” “intends,” “estimates,” “seeks,” “may,” “might,” “plan,” “possible,” “should” and variations and similar words and expressions are intended to identify such forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements relate to future events or future results, based on currently available information and reflect the Company’s management’s current beliefs. A number of factors could cause actual events or results to differ materially from the events and results discussed in the forward-looking statements. Important factors – including the availability of funds, the results of financing efforts and the risks relating to our business – that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on EDGAR (see www.edgar-online.com) and with the Securities and Exchange Commission (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Investor Relations

Michael J. Porter, President
PORTER, LEVAY & ROSE, INC.
mike@plrinvest.com

SOURCE: EON Resources Inc.

View the original press release on ACCESS Newswire

From Tax Bracket Adjustments to New Audit Priorities, Clear Start Tax Helps Taxpayers Navigate the Year’s Key IRS Changes

IRVINE, CALIFORNIA / ACCESS Newswire / May 21, 2025 / With major IRS updates rolling out in 2025, Clear Start Tax, a nationally recognized tax resolution firm, is helping Americans understand what these changes mean for their finances, tax returns, and audit exposure. While the IRS is expanding enforcement efforts, it’s also introducing key adjustments and opportunities that taxpayers should understand before they file.

From inflation adjustments to new enforcement priorities, Clear Start Tax breaks down what taxpayers need to know to stay informed and protected.

Preparing Taxpayers for 2025: Clear Start Tax’s Guide to IRS Changes

Clear Start Tax is helping taxpayers stay informed and prepared as the IRS rolls out several important policy changes for 2025. From updated tax brackets to expanded retirement limits, here’s what individuals and families need to know to plan ahead.

Inflation-Adjusted Tax Brackets and Standard Deductions

According to Clear Start Tax, to keep pace with rising costs, the IRS has increased tax bracket thresholds and standard deductions for 2025.

• Standard deduction increases:

  • Single filers: $15,000 (up from $14,600)

  • Married filing jointly: $30,000 (up from $29,200)

  • Heads of household: $22,500 (up from $21,900)

• Tax bracket adjustments:
  Income thresholds have been raised by roughly 2.8% to help taxpayers avoid being pushed into higher brackets due to inflation alone.

Retirement Contribution Limit Enhancements

Clear Start Tax shares good news for retirement savers: the IRS has raised contribution limits for 2025.

• 401(k), 403(b), 457 plans: $23,500 (up from $23,000)

• Catch-up contributions:

  • Age 50+: $7,500

  • New for ages 60-63: $11,250, bringing total potential contributions to $34,750

Estate and Gift Tax Exclusion Increase

Families making long-term plans will benefit from expanded limits:

• Individuals: $13.99 million (up from $13.61 million)

• Married couples: $27.98 million

Expanded IRS Direct File Program

More taxpayers now have access to free IRS filing options:

• Available in 24 states

• Now covers taxpayers with 1099 income and credits like the Child and Dependent Care Credit

Increased Focus on High-Income Audits

Clear Start Tax warns that IRS enforcement will increasingly target:

• High-income households

• Cryptocurrency transactions

• Small businesses claiming large deductions

This shift makes careful tax preparation, documentation, and professional guidance more important than ever.

“Understanding these updates is critical to making informed tax decisions and avoiding surprises,” said the Head of Client Solutions at Clear Start Tax. “We help our clients navigate these new rules, protect their finances, and stay compliant with confidence.”

How Clear Start Tax Helps Taxpayers Stay Prepared

With new policies come new risks-and opportunities. Clear Start Tax provides:

• Personalized financial reviews to assess impact

• Guidance on selecting the right IRS relief programs

• Expert negotiation and communication with the IRS

• Ongoing compliance support to avoid penalties or audits

About Clear Start Tax

Clear Start Tax is a full-service tax liability resolution firm that serves taxpayers throughout the United States. The company specializes in assisting individuals and businesses with a wide range of IRS and state tax issues, including back taxes, wage garnishment relief, IRS appeals, and offers in compromise. Clear Start Tax helps taxpayers apply for the IRS Fresh Start Program, providing expert guidance in tax resolution. Fully accredited and A+ rated by the Better Business Bureau, the firm’s unique approach and commitment to long-term client success distinguish it as a leader in the tax resolution industry.

Need Help With Back Taxes?

Click the link below:
https://clearstarttax.com/qualifytoday/

Contact Information

Clear Start Tax
Corporate Communications Department
seo@clearstarttax.com
(949) 535-1627

SOURCE: Clear Start Tax

View the original press release on ACCESS Newswire